3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Sarcoma
1
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
20
Meningioma
6
Gastro-enteropancreatic neuroendocrine tumor
6
Pheochromocytoma
3
Paraganglioma
3
Prostatic Neoplasms
2
Neuroblastoma
2
Medulloblastoma
2
Glioma
2
Glioblastoma
2
Ependymoma
2
Carcinoma, Merkel Cell
2
Adenoma, Islet Cell
2
Somatostatin Receptor-positive Neuroendocrine Tumor
1
Sarcoma, Synovial
1
Recurrence
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasms, Germ Cell and Embryonal
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Hypertension
1
Extensive Stage Small Cell Lung Cancer
1
Esthesioneuroblastoma, Olfactory
1
Disease Progression
1
Digestive System Neuroendocrine Tumor G1
1
Diffuse Intrinsic Pontine Glioma
1
Central Nervous System Neoplasms
1
Carcinoma, Neuroendocrine
1
Carcinoma
1
Carcinoid Tumor
1
Interventions
Cyclophosphamide
28
Temozolomide
25
Irinotecan
21
dinutuximab
20
Topotecan
15
Magnetic Resonance Spectroscopy
13
Specimen Handling
12
Biopsy
12
naxitamab
11
Granulocyte-Macrophage Colony-Stimulating Factor
11
3-Iodobenzylguanidine
11
Vincristine
10
Etoposide
10
sargramostim
9
Melphalan
9
Isotretinoin
9
fludarabine
8
X-Rays
8
Colony-Stimulating Factors
8
Carboplatin
8
etoposide phosphate
7
Phantoms, Imaging
7
Doxorubicin
7
fludarabine phosphate
6
Stem Cell Transplantation
6
Nuclear Medicine Department, Hospital
6
Eflornithine
6
Thiotepa
5
Granulocyte Colony-Stimulating Factor
5
Filgrastim
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neuroblastoma
×
lutetium Lu 177 dotatate
×
1 year
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled
NCT03966651
2026-04-29
NEUROBLU 02
Institut Claudius Regaud
Phase 1
Completed
1 enrolled